ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated
May 10, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, May 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
April 28, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...